Lexicon Pharmaceuticals, Inc. (LXRX)
$
0.44
-0.06 (-13.64%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Lexicon Pharmaceuticals, Inc. is dedicated to the discovery, development, and commercialization of pharmaceutical products, having achieved a revenue of $31,081,000.00 indicating its niche market focus. The cost of revenue for the company is $616,000.00 showcasing its production and operational expenses. The company’s stock is identified with the symbol 'LXRX' in the market, and its gross profit ratio stands at 0.98 reflecting the efficiency of the company's production and sales operations. Furthermore, the operating income ratio is -6.34 indicating the company's operational profitability margin. The company is engaged in the development of orally-delivered small molecule drug candidates, including Sotagliflozin, which has successfully completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, as well as LX9211, currently in Phase II clinical development for neuropathic pain management. Lexicon also maintains strategic collaborations and license agreements with Bristol-Myers Squibb Company and Genentech, Inc., enhancing its market presence. Founded in 1995, the company is headquartered in The Woodlands, Texas. In the investment landscape, the stock is affordable at $0.58 making it suitable for budget-conscious investors. Additionally, the stock exhibits a high average trading volume of 14,884,965.00 indicating strong liquidity. With a market capitalization of $160,213,254.00 the company is classified as a small-cap player within the biopharmaceutical sector. Lexicon Pharmaceuticals, Inc. is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its field. Through its robust pipeline and strategic partnerships, Lexicon continues to strive toward enhancing healthcare outcomes while providing investors with potential opportunities for growth in a rapidly evolving market.
Is Lexicon Pharmaceuticals, Inc. (LXRX) a good investment?
Investing in Lexicon Pharmaceuticals, Inc. (LXRX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Lexicon Pharmaceuticals, Inc. (LXRX)'s stock forecast?
Analysts predict Lexicon Pharmaceuticals, Inc. stock to fluctuate between $0.28 (low) and $2.45 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Lexicon Pharmaceuticals, Inc.'s market capitalization?
As of 2025-04-04, Lexicon Pharmaceuticals, Inc.'s market cap is $160,213,254, based on 361,492,000 outstanding shares.
How does Lexicon Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Lexicon Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Lexicon Pharmaceuticals, Inc. (LXRX) stock?
To buy Lexicon Pharmaceuticals, Inc. (LXRX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LXRX. Place an order (Market, Limit, etc.).
What is the best time to invest in Lexicon Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Lexicon Pharmaceuticals, Inc. stock ever split?
Lexicon Pharmaceuticals, Inc.'s last stock split was 1:7 on 2015-05-21.
How did Lexicon Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $31,081,000 | EPS: -$0.63 | Growth: -21.25%.
Where can I find Lexicon Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.lexpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Lexicon Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Lexicon Pharmaceuticals, Inc. stock?
All-time high: $9.65 (2021-02-02) | All-time low: $0.28 (2025-03-03).
What are the key trends affecting Lexicon Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
globenewswire.com
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments
seekingalpha.com
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Co. Joe Pantginis - H.C. Wainwright Andrew Tsai - Jefferies Operator Welcome to the Lexicon Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call.
zacks.com
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago.
globenewswire.com
THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.
globenewswire.com
THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will hold a conference call and webcast on Monday, March 3, 2025 at 8:00 a.m. ET to share topline results from the Phase 2b PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor in adult patients with moderate to severe diabetic peripheral neuropathic pain (DPNP).
globenewswire.com
Event will feature insights on LX9211, Lexicon's novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP Event will feature insights on LX9211, Lexicon's novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP
globenewswire.com
THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025.
reuters.com
The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.
globenewswire.com
THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Zynquista™ (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). This expected communication from the FDA aligns with the company's previously disclosed strategic decision to discontinue launch preparations for Zynquista and focus solely on its clinical development pipeline.
See all news
